

National Library of Medicine; Notice of Meeting of the Board of Scientific Counselors, National Center for Biotechnology Information, National Library of Medicine

Pursuant to Pub. L. 92-463, notice is hereby given of the meeting of the Board of Scientific Counselors, National Center for Biotechnology Information, National Library of Medicine, on October 28-29, 1996.

The meeting on October 29 will be open to the public from 9 a.m. to 3 p.m. in the Board Room of the Library, 8600 Rockville Pike, Bethesda, Maryland, for the review of research and development programs and preparation of reports of the National Center for Biotechnology Information. Attendance by the public will be limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should contact Dr. David Lipman at 301-496-2475.

In accordance with provisions set forth in sec. 552b(c)(6), Title 5 U.S.C., and sec. 10(d) of Pub. L. 92-463, the meeting will be closed to the public on October 28 from 7 p.m. to approximately 10 p.m., at the Bethesda Hyatt Hotel, and on October 29, from 3 p.m. to approximately 5 p.m., in the Board Room of the National Library of Medicine, for the consideration of personnel qualifications and performance of individual investigators and similar items, the disclosure of which would constitute an unwarranted invasion of personal privacy.

The Executive Secretary, Dr. David J. Lipman, Director, National Center for Biotechnology Information, National Library of Medicine, 8600 Rockville Pike, Bethesda, Maryland 20894, telephone (301) 496-2475, will furnish summaries of the meeting, rosters of committee members, and substantive program information.

Dated: September 19, 1996.
Paula N. Hayes,
Acting Committee Management Officer, NIH.
[FR Doc. 96-24612 Filed 9-25-96; 8:45 am]
BILLING CODE 4140-01-M

National Library of Medicine; Notice of Meeting of the Literature Selection Technical Review Committee

Pursuant to Pub. L. 92-463, notice is hereby given of a meeting of the Literature Selection Technical Review Committee, National Library of Medicine, on October 24-25, 1996, convening at 9 a.m. on October 24 and 8:30 a.m. on October 25 in the Board

Room of the National Library of Medicine, Building 38, 8600 Rockville Pike, Bethesda, Maryland.

The meeting on October 24 will be open to the public from 9 a.m. to approximately 10:30 a.m. for the discussion of administrative reports and program developments. Attendance by the public will be limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should contact Mrs. Lois Ann Colaanni at 301-496-6921 two weeks before the meeting.

In accordance with provisions set forth in sec. 552b(c)(9)(B), Title 5 U.S.C., Pub. L. 92-463, the meeting will be closed on October 24 from 10:30 a.m. to approximately 5 p.m. and on October 25 from 8:30 a.m. to adjournment for the review and discussion of individual journals as potential titles to be indexed by the National Library of Medicine. The presence of individuals associated with these publications could hinder fair and open discussion and evaluation of individual journals by the Committee members.

Mrs. Lois Ann Colaanni, Scientific Review Administrator of the Committee, and Associate Director, Library Operations, National Library of Medicine, 8600 Rockville Pike, Bethesda, Maryland 20894, telephone number: 301-496-6921, will provide a summary of the meeting, rosters of the committee members, and other information pertaining to the meeting.

Dated: September 19, 1996.
Paula N. Hayes,
Acting Committee Management Officer, NIH.
[FR Doc. 96-24613 Filed 9-25-96; 8:45 am]
BILLING CODE 4140-01-M

National Library of Medicine; Notice of Meeting of the Biomedical Library Review Committee

Pursuant to Pub. L. 92-463, notice is hereby given of the meeting of the Biomedical Library Review Committee on November 6-7, 1996, convening at 8:30 a.m. in the Board Room of the National Library of Medicine, Building 38, 8600 Rockville Pike, Bethesda, Maryland.

The meeting on November 6 will be open to the public from 8:30 a.m. to approximately 11 a.m. for the discussion of administrative reports and program developments. Attendance by the public will be limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should

contact Dr. Roger W. Dahlen at 301-496-4221 two weeks before the meeting.

In accordance with provisions set forth in secs. 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., and sec. 10(d) of Pub. L. 92-463, the meeting on November 6 will be closed to the public for the review, discussion, and evaluation of individual grant applications from 11 a.m. to approximately 5 p.m., and on November 7 from 8:30 a.m. to adjournment. These applications and the discussion could reveal confidential trade secrets or commercial property, such as patentable material, and personal information concerning individuals associated with the applications, disclosure of which would constitute a clearly unwarranted invasion of person privacy.

Dr. Roger W. Dahlen, Scientific Review Administrator, and Chief, Biomedical Information Support Branch, Extramural Programs, National Library of Medicine, 8600 Rockville Pike, Bethesda, Maryland 20894, telephone number: 301-496-4221, will provide summaries of the meeting, rosters of the committee members, and other information pertaining to the meeting.

(Catalog of Federal Domestic Assistance Program No. 93.879—Medical Library Assistance, National Institutes of Health)

Dated: September 18, 1996.
Paula N. Hayes,
Acting Committee Management Officer, NIH.
[FR Doc. 96-24620 Filed 9-25-96; 8:45 am]
BILLING CODE 4140-01-M

Division of Research Grants; Notice of Closed Meeting

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting:

Purpose/Agenda: To review and evaluate grant applications.

Name of Committee: Safety and Occupational Health Study Section.

Dates of Meeting: October 10-11, 1996.

Time: 8:00 a.m.

Place of Meeting: Pooks Hill Marriott Hotel, Bethesda, Maryland.

Contact Person: Dr. Pervis C. Major, 1095 Willowdale Road, Room P-146, Morgantown, West Virginia 26505, (304) 285-5910.

The meeting will be closed in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C. Applications and/or proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

This notice is being published less than fifteen days prior to the meeting due to the urgent need to meet timing limitations imposed by the grant review and funding cycle.

(Catalog of Federal Domestic Assistance Program Nos. 93.306, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: September 20, 1996.

Paula N. Hayes,

Acting Committee Management Officer, NIH.

[FR Doc. 96–24730 Filed 9–25–96; 8:45 am]

BILLING CODE 4140–01–M

National Cancer Institute; Office of Cancer Communications; Notice of Partnership Initiative

Pursuant to Pub. L. 92–463, notice is hereby given that the Office of Cancer Communications, National Cancer Institute, is seeking partnerships with non-Federal organizations to conduct public awareness programs on cancer research, patient education, clinical trials, screening, prevention, genetics education, and cancer risk communication. The goal is to strengthen the National Cancer Program by forming partnerships with private sector organizations. These cooperative efforts are intended to bring the resources of several partners to bear on cancer-related problems that are too complex or massive for any one organization to handle alone.

Note: Partnerships between NCI and outside organizations will be formalized through Memorandum of Agreements and will not involve grants or contracts.

Date of Effectiveness: Beginning immediately.

For more information, please contact John Burklow, Office of Cancer Communications, National Cancer Institute, at (301) 496–6631.

Dated: September 12, 1996.

Philip D. Amoruso,

Director, Office of Extramural Management.

[JR Dos. 96–24625 Filed 9–25–96; 8:45 am]

BILLING CODE 4140–01–M

Public Health Service

The National Toxicology Program (NTP) Revised Criteria and Process for Listing Substances in the Biennial Report on Carcinogens

AGENCY: National Institute of Environmental Health Sciences, Public Health Service, HHS.

ACTION: Notice.

SUMMARY: The Department of Health and Human Services is providing this notice

of changes in the criteria for listing carcinogens in the Biennial Report on Carcinogens. The process for developing these changes was public and included participation of a broad base of interested parties. The revised criteria will be used to develop the eighth annual report.

FOR FURTHER INFORMATION CONTACT: Dr. C.W. Jameson, NIEHS/NTP, Biennial Report on Carcinogens, MD WC–05, P.O. Box 12233, Research Triangle Park, North Carolina 27709; fax 919 541–2242; internet Jameson@niehs.nih.gov.

SUPPLEMENTARY INFORMATION:

Background

Section 301(b)(4) of the Public Health Service Act, as amended, provides that the Secretary, Department of Health and Human Services (HHS), shall publish a report which contains a list of all substances (1) which either are known to be human carcinogens or may reasonably be anticipated to be human carcinogens; and (2) to which a significant number of persons residing in the United States (US) are exposed. The Biennial Report on Carcinogens is prepared by the National Toxicology Program (NTP).

A review of the criteria used to list substances in the Report was initiated by the Director, NTP in late 1994. The process for the review was public and included participation of a broad base of interested persons including Academia, Industry, Labor, Federal, State and Local Agencies and Private Organizations. During 1995 the review included two open, public meetings by the NTP Board of Scientific Counselors and a number of internal reviews by HHS and the NTP Executive Committee agencies.

At each step of the review there was concurrence with the following points: (1) the current criteria should be revised; (2) mechanistic information should be used as part of the listing criteria; (3) the categories (known to be human carcinogens and reasonably anticipated to be human carcinogens) should remain the same as described in the original legislation; and (4) there should be a formal mechanism which allows for the removal of substances from the BRC. Based on these recommendations, revised criteria and a new procedure for applying these criteria for inclusion or removal of substances in the BRC were prepared by the NTP with the assistance of NTP participating agencies.

Revised Criteria

A point by point comparison of the former BRC criteria to the revised criteria follows. Sections that have been

deleted from the former BRC criteria are in brackets []. The changes/additions in the revised criteria are highlighted by underlining.

Former BRC Criteria Known To Be Carcinogens

There is sufficient evidence of carcinogenicity from studies in humans which indicates a causal relationship between the agent and human cancer.

Revised BRC Criteria Known To Be Human Carcinogens

There is sufficient evidence of carcinogenicity from studies in humans which indicates a causal relationship between *exposure to the agent, substance or mixture* and human cancer.

Former BRC Criteria Reasonably Anticipated To Be Carcinogens

[a.] There is limited evidence of carcinogenicity from studies in humans, which indicates that causal interpretation is credible, but that alternative explanations, such as chance, bias or confounding, could not adequately be excluded, or

[b.] There is sufficient evidence of carcinogenicity from studies in experimental animals which indicates that there is an increased incidence of malignant tumors: (a) in multiple species [or strains], or (b) [in multiple experiments (preferably with different routes of administration or using different dose levels)], or (c) to an unusual degree with regard to incidence, site or type of tumor, or age at onset. Additional evidence may be provided by data concerning dose-response effects, as well as information on mutagenicity or chemical structure.]

Revised BRC Criteria Reasonably Anticipated To Be Human Carcinogens

There is limited evidence of carcinogenicity from studies in humans, which indicates that causal interpretation is credible, but that alternative explanations, such as chance, bias or confounding, could not adequately be excluded, or

There is sufficient evidence of carcinogenicity from studies in experimental animals which indicates that there is an increased incidence of malignant *and/or combined benign and malignant tumors*: (a) in multiple species *or at multiple tissue sites*, or (b) *by multiple routes of exposure*, or (c) to an unusual degree with regard to incidence, site or type of tumor, or age at onset; or

There is less than sufficient evidence of carcinogenicity in humans or laboratory animals, however; the agent,